1. Preferential tax policies to promote investment: preferential venture capital. In order to encourage the development of small and medium-sized high-tech biopharmaceutical enterprises, if venture capital enterprises invest in unlisted small and medium-sized high-tech biopharmaceutical enterprises for more than two years, 70% of their investment amount can be deducted from the taxable income of venture capital enterprises in the year when their shares have been held for two years; If the deduction is insufficient in the current year, it can be carried forward in future tax years. Investment income is tax-free. In order to avoid double taxation and encourage enterprises to invest, dividends, bonuses and other equity investment income obtained by qualified resident enterprises directly investing in biomedical enterprises are exempted from enterprise income tax.

2. Preferential tax policies to promote scientific and technological progress: High-tech enterprises enjoy low tax rates, and high-tech enterprises that need key state support are subject to enterprise income tax at a reduced rate of 15%. Accelerated depreciation of fixed assets. If it is really necessary to accelerate the depreciation of fixed assets of enterprises due to technological progress, the depreciation period can be shortened or the accelerated depreciation method can be adopted. R&D expenses are deducted before tax. If the R&D expenses incurred by biomedical enterprises for developing new technologies, new products and new processes are not included in the current profits and losses, they shall be deducted according to 50% of the R&D expenses on the basis of actual deduction according to regulations; Intangible assets shall be amortized at 150% of the cost of intangible assets. The Notice on Policy Issues Concerning Pre-tax Plus Deduction of R&D Expenses (Caishui [2013] No.70) included the clinical trial expenses of new drug research and development into the scope of plus deduction.

3. Preferential tax policies to promote the integrated development of Industry-University-Research: incubator preferential policies. According to the Notice of State Taxation Administration of The People's Republic of China, Ministry of Finance of People's Republic of China (PRC) on Tax Policies for Incubators of Science and Technology Enterprises (Caishui [2013]17), the income of incubators that meet the requirements of non-profit organizations shall enjoy preferential corporate income tax policies in accordance with the Enterprise Income Tax Law and its implementing regulations and relevant tax policies. Our province's science and technology biomedical business incubator can apply to the finance and taxation department for recognition as a non-profit organization, and its non-profit income enjoys enterprise income tax exemption. Technology transfer income can be reduced or exempted, and the technology transfer income of qualified biomedical enterprises can be reduced or exempted. Specifically, in a tax year, the part of the technology transfer income of resident enterprises that does not exceed 5 million yuan shall be exempted from enterprise income tax; For the part exceeding 5 million yuan, the enterprise income tax will be levied by half. The scope of technology transfer includes new varieties of biomedicine and other technology transfer determined by the Ministry of Finance of People's Republic of China (PRC) and State Taxation Administration of The People's Republic of China. At the same time, enterprises should sign technology transfer contracts and separately account for technology transfer income.